论文部分内容阅读
目的研究人参皂苷水解脱糖产物DS-1226对慢性限制活动大鼠的抗抑郁作用,为抗抑郁药物的研发提供实验数据。方法将90只雄性Sprague-Dawley大鼠随机分为6组,每组15只,分别为对照组(control)、模型组(model)、西酞普兰组(citalopram,100 mg/kg)、低剂量组(DS-1226,18.75 mg/kg)、中剂量组(DS-1226,37.5mg/kg)、高剂量组(DS-1226,75 mg/kg)。预防7 d给药后进行每天14 h连续28 d的限制活动造模并连续给药。造模过程中每周监测体重并在造模完成后进行糖水偏爱、新奇事物、自主活动实验,测试完成后处死动物取血清检测皮质酮含量。结果经过慢性限制活动应激后,模型组大鼠的体重和糖水偏爱指数降低,对新奇事物的探索行为以及自主活动尤其是中央区的活动减少,血中的皮质酮含量升高。但中剂量、高剂量的DS-1226和西酞普兰能不同程度的提高慢性限制活动大鼠的体重和糖水偏爱指数,增加对新奇事物的探索次数、探索时间、降低潜伏期时间,增加自主活动尤其是中央区的活动,降低血中皮质酮的含量。结论 DS-1226具有改善慢性限制活动大鼠抑郁行为的作用。
Objective To study the antidepressant effect of ginsenoside hydrolysis de-saccharide DS-1226 on rats with chronic limitation of activity and to provide experimental data for the development of anti-depressant drugs. Methods Ninety male Sprague-Dawley rats were randomly divided into 6 groups with 15 rats in each group: control, model, citalopram (100 mg / kg), low dose (DS-1226, 18.75 mg / kg), middle dose group (DS-1226, 37.5 mg / kg) and high dose group (DS-1226, 75 mg / kg). Prevention of 7 d after administration of 14 h daily for 28 consecutive days of limiting activity modeling and continuous administration. During the modeling process, the body weight was monitored weekly and sugar preference, novelty and autonomic activity were tested after the model was finished. The animals were sacrificed to determine the corticosterone level after the test was completed. Results After chronic limitation of activity stress, the body weight and glyphosate preference index of model rats decreased, the exploring behavior of novelty and activities of autonomic activity especially in central area decreased, and the content of corticosterone in blood increased. However, moderate and high doses of DS-1226 and citalopram can increase the body weight and glycosylated preference index of rats with chronic limitation of activity to some extent, increase the exploration of novelty, explore time, reduce latency and increase autonomic activity Is a central activity that reduces blood levels of corticosterone. Conclusions DS-1226 can improve the depressive behavior of rats with chronic limitation of action.